| Date | Title | |
| 12/03/12 | Alkermes and Collaborators to Present Data from Three Ongoing Clinical Development Programs at Two Major Medical Meetings |  |
| 11/07/12 | Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences | |
| 11/01/12 | Alkermes plc Reports Second Quarter Fiscal 2013 Financial Results | |
| 10/25/12 | Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2013 | |
| 09/25/12 | Alkermes plc Closes Debt Refinancing, Lowering Interest Rate and Reducing Principal Amount | |
| 09/19/12 | Alkermes plc Announces Pricing of New Term Loans | |
| 08/30/12 | Alkermes’ Corporate Presentation to Be Webcast at Two Upcoming Conferences | |
| 07/26/12 | Alkermes plc Reports First Quarter Fiscal 2013 Financial Results | |
| 07/19/12 | Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2013 | |
| 06/12/12 | INVEGA® SUSTENNA® Three-Month Formulation of Paliperidone Palmitate Enters Phase 3 Clinical Program for Schizophrenia | |
| 06/09/12 | BYDUREON™ Was Associated with Significant and Sustained Glycemic Control at Four Years | |
| 06/09/12 | BYDUREON™ Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes | |
| 06/09/12 | Once-Weekly BYDUREON™ Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 Diabetes | |
| 05/31/12 | Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences | |
| 05/30/12 | Alkermes Announces Results from Phase 2 Study of ALKS 37 for Treatment of Opioid-Induced Constipation | |
| 05/29/12 | Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug Evaluation Unit Meeting | |
| 05/17/12 | Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 | |
| 05/10/12 | Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2012 | |
| 05/03/12 | VIVITROL(R) Data to be Presented at Upcoming American Psychiatric Association Annual Meeting | |
| 03/13/12 | Alkermes plc Completes Secondary Offering of 24,150,000 Ordinary Shares Held by Elan | |
| 03/08/12 | Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary Shares Held by Elan | |
| 03/07/12 | Alkermes plc Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan | |
| 03/05/12 | Alkermes Appoints Mark Stejbach as Chief Commercial Officer | |
| 02/27/12 | Alkermes’ Corporate Presentation to be Webcast at the Cowen & Company 32nd Annual Health Care Conference | |
| 02/16/12 | Alkermes Files Resale Shelf Registration in Connection with Elan Shareholder Agreement | |
| 02/13/12 | BYDUREON™, First and Only Once-Weekly Type 2 Diabetes Treatment, Now Available in U.S. Pharmacies | |
| 02/09/12 | Alkermes' Corporate Presentation to be Webcast at the Leerink Swann 2012 Global Healthcare Conference | |
| 02/06/12 | Alkermes’ Corporate Presentation to be Webcast at the 14th Annual BIO CEO & Investor Conference | |
| 02/02/12 | Alkermes plc Reports Third Quarter Fiscal 2012 Financial Results | |
| 01/31/12 | Alkermes Initiates Open-Label Pilot Study of VIVITROL® to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence | |
| 01/27/12 | FDA Approves BYDUREON™ -- The First and Only Once-Weekly Treatment for Type 2 Diabetes | |
| 01/26/12 | Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2012 | |
| 01/04/12 | Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder | |
| 01/03/12 | Alkermes’ Corporate Presentation to be Webcast at the 30th Annual J.P. Morgan Healthcare Conference | |
